CG Oncology, Inc.
Clinical trials sponsored by CG Oncology, Inc., explained in plain language.
A biopharmaceutical company developing immunotherapies for bladder cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Bladder cancer breakthrough? virus therapy aims to stop recurrence Results expected Nov 2026 (estimated) May already have reported ↗ 🚀 Make-or-break
- Bladder cancer virus therapy shows promise in Mid-Stage trial Results expected Mar 2027 (estimated) May already have reported ↗
-
Virus therapy shows promise for tough bladder cancer cases
Disease control OngoingThis phase 3 trial is testing a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not improve after standard BCG therapy. The treatment uses a modified virus to target and destroy cancer cells. About 190 pa…
Phase 3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Bladder cancer breakthrough? virus therapy aims to stop recurrence
Disease control OngoingThis phase 3 trial tests whether a virus-based drug called cretostimogene grenadenorepvec can prevent intermediate-risk bladder cancer from coming back after surgery. About 367 participants will either receive the drug or be monitored as usual. The goal is to see if the treatment…
Phase 3 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New Virus-Based therapy targets bladder cancer after BCG fails
Disease control CancelledThis study tested a treatment called CG0070, a virus designed to attack cancer cells, in people with high-grade non-muscle invasive bladder cancer. Participants had already tried standard therapy (BCG) without success and chose not to have their bladder removed. The goal was to s…
Phase 2 • Sponsor: CG Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC